Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 trial of LB-001

Trial Profile

Phase 1/2 trial of LB-001

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 13 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LB 001 (Primary)
  • Indications Methylmalonic acidaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors LogicBio Therapeutics
  • Most Recent Events

    • 13 Aug 2019 According to an LogicBio Therapeutics media release, this trial is expected to begin in 1H 2020 and preliminary data is anticipated in 2H 2020.
    • 13 Aug 2019 According to an LogicBio Therapeutics media release, the company plans to file an Investigational New Drug application for LB-001 in the fourth quarter of 2019 and the details regarding clinical trial size, endpoints and timelines to be communicated upon IND acceptance.
    • 22 Feb 2019 According to a LogicBio media release, Dr. Kenneth Huttner will lead IND-enabling studies and upcoming clinical trials of LB-001.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top